In addition, the phase II MIRACLE study, conducted within the Chinese population, confirmed that everolimus combined with endocrine therapy as a first‐line treatment significantly extends PFS in premenopausal HR‐positive/HER2‐negative advanced breast cancer patients with endocrine treatment failure compared to endocrine therapy alone (19.4 vs. 12.9 months) [57]. The gene discussed is ERBB2; the disease is breast cancer.